News & Events about Ardelyx Inc.
StockNews.com upgraded shares of Ardelyx (NASDAQ:ARDX Get Rating) from a hold rating to a buy rating in a research note published on Wednesday. Separately, Wedbush increased their target price on Ardelyx from $6.00 to $7.00 and gave the stock an outperform rating in a research note on Monday, April ...
WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the...
Ardelyx, Inc. (NASDAQ:ARDX Get Rating)s share price reached a new 52-week high during mid-day trading on Monday after Wedbush raised their price target on the stock from $6.00 to $7.00. Wedbush currently has an outperform rating on the stock. Ardelyx traded as high as $5.13 and last traded at $4.98...
StockNews.com lowered shares of Ardelyx (NASDAQ:ARDX Get Rating) from a buy rating to a hold rating in a report published on Wednesday. Several other equities analysts have also recently issued reports on the company. Citigroup boosted their price target on Ardelyx from $6.00 to $7.00 and ...
StockNews.com cut shares of Ardelyx (NASDAQ:ARDX Get Rating) from a buy rating to a hold rating in a research report sent to investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Citigroup lifted their target price on Ardelyx from $6.00 to...